LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
-11.95%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$545M
AUM Growth
+$545M
(-29%)
Cap. Flow
-$111M
Cap. Flow
% of AUM
-20.36%
Top 10 Holdings %
Top 10 Hldgs %
72.8%
Holding
51
New
4
Increased
7
Reduced
16
Closed
19
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$30M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$27.9M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$27.1M |
| 4 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$14.9M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$12.6M |
Top Sells
Sector Composition
| 1 | Healthcare | 97.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cytokinetics
CYTK
$4.23B
| $68.8M | 12.61% |
1,750,000
+135,000
| +8% | +$5.3M |
|
|
2
Apellis Pharmaceuticals
APLS
$3.48B
| $67.8M | 12.44% |
1,500,000
+600,000
| +67% | +$27.1M |
|
3
IDEAYA Biosciences
IDYA
$2.15B
| $51.8M | 9.49% |
3,750,000
+900,000
| +32% | +$12.4M |
|
4
Design Therapeutics
DSGN
$315M
| $39.2M | 7.19% |
2,797,501
| – | – |
|
|
5
Sarepta Therapeutics
SRPT
$1.78B
| $30M | 5.5% |
+400,000
| New | +$30M |
|
6
Neurocrine Biosciences
NBIX
$13.8B
| $29.2M | 5.37% |
300,000
-175,000
| -37% | -$17.1M |
|
|
BCYC
7
Bicycle Therapeutics
BCYC
$511M
| $28.5M | 5.23% |
1,700,000
+750,000
| +79% | +$12.6M |
|
8
Ventyx Biosciences
VTYX
$171M
| $28.3M | 5.19% |
2,312,680
-201,600
| -8% | -$2.47M |
|
|
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $27.9M | 5.12% |
+350,000
| New | +$27.9M |
|
10
ALX Oncology
ALXO
$62.7M
| $25.4M | 4.66% |
3,136,352
+125,000
| +4% | +$1.01M |
|
11
Arcutis Biotherapeutics
ARQT
$1.86B
| $21.3M | 3.91% |
1,000,000
-500,000
| -33% | -$10.7M |
|
12
Dyne Therapeutics
DYN
$1.92B
| $19.9M | 3.66% |
2,900,000
+165,608
| +6% | +$1.14M |
|
|
KRTX
13
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $19M | 3.48% |
150,000
-190,000
| -56% | -$24M |
|
|
DICE
14
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $15.3M | 2.81% |
985,251
-400,000
| -29% | -$6.21M |
|
15
Olema Pharmaceuticals
OLMA
$375M
| $15.2M | 2.8% |
3,743,875
| – | – |
|
|
CCXI
16
DELISTED
ChemoCentryx, Inc.
CCXI
| $14.9M | 2.73% |
+600,000
| New | +$14.9M |
|
17
Fulcrum Therapeutics
FULC
$351M
| $9.56M | 1.75% |
1,950,000
+950,000
| +95% | +$4.66M |
|
18
Acadia Pharmaceuticals
ACAD
$4.38B
| $9.16M | 1.68% |
+650,000
| New | +$9.16M |
|
19
Kezar Life Sciences
KZR
$28.9M
| $7.86M | 1.44% |
950,000
-664,021
| -41% | -$5.49M |
|
20
Century Therapeutics
IPSC
$42.5M
| $4M | 0.73% |
476,559
-73,700
| -13% | -$619K |
|
|
CNTA
21
Centessa Pharmaceuticals
CNTA
$2.25B
| $1.95M | 0.36% |
399,801
-54,744
| -12% | -$267K |
|
|
SPRB
22
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
| $1.74M | 0.32% |
1,000,000
| – | – |
|
23
Instil Bio
TIL
$182M
| $1.71M | 0.31% |
369,800
-7,291
| -2% | -$33.7K |
|
24
Tourmaline Bio
TRML
$601M
| $1.22M | 0.22% |
270,987
-35,249
| -12% | -$159K |
|
25
Edgewise Therapeutics
EWTX
$1.51B
| $1.19M | 0.22% |
150,000
-63,744
| -30% | -$507K |
|